Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Has $1.11 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 28.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,928 shares of the company's stock after selling 20,882 shares during the quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group's holdings in Kenvue were worth $1,109,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of KVUE. Huntington National Bank lifted its position in shares of Kenvue by 26.5% in the third quarter. Huntington National Bank now owns 4,161 shares of the company's stock worth $96,000 after purchasing an additional 871 shares in the last quarter. ING Groep NV lifted its position in shares of Kenvue by 23.6% in the third quarter. ING Groep NV now owns 3,576,616 shares of the company's stock worth $82,727,000 after purchasing an additional 681,954 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Kenvue by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after purchasing an additional 21,222 shares in the last quarter. Alberta Investment Management Corp lifted its position in shares of Kenvue by 23.2% in the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after purchasing an additional 109,700 shares in the last quarter. Finally, Longbow Finance SA lifted its position in shares of Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after purchasing an additional 13,287 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Remove Ads

Kenvue Stock Performance

Shares of NYSE:KVUE traded down $0.37 on Friday, hitting $22.81. The company had a trading volume of 15,798,851 shares, compared to its average volume of 14,714,287. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The stock has a market cap of $43.59 billion, a price-to-earnings ratio of 43.03, a P/E/G ratio of 2.62 and a beta of 1.25. The stock has a 50 day moving average price of $21.84 and a 200 day moving average price of $22.38. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.60%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group dropped their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.